Cost & Insurance Navigation

Let’s talk about the number that stops people in their tracks. You’ve had the conversation with your doctor, you’ve decided a GLP-1 medication is right for you, and then someone — a pharmacist, an insurance rep, a billing department — tells you the price. And the number doesn’t make sense. $936 a month. $1,349 a month. For a medication your doctor says you need.

If you’ve had that moment, you’re not alone. Cost is the single biggest barrier to GLP-1 access in the United States right now. Not side effects, not eligibility, not availability — money. And the system that determines what you actually pay is so opaque that most people don’t know where to start.

This page won’t fix the system. But it will give you a clear picture of what these medications actually cost, what the different coverage pathways look like, and what strategies real people are using to make treatment affordable. The landscape is also changing fast — faster than most guides can keep up with — so we’ll cover where things stand right now and what’s coming.

The Sticker Shock: List Prices vs. Reality

Here’s the first thing to understand: almost nobody pays the list price. The list price (sometimes called the WAC, or wholesale acquisition cost) is essentially the manufacturer’s starting number before any discounts, insurance negotiations, or savings programs. It’s real, but it’s not what most people actually pay.

That said, here are the list prices as of early 2026:

Those numbers are jarring. They’re supposed to be. The list price is a negotiating tool — it’s the ceiling that insurers, pharmacy benefit managers (the companies that negotiate drug prices on behalf of insurers), and government programs bargain down from. The actual price paid by any given person depends on their insurance, their diagnosis code, their savings card, and sometimes pure luck.

Insurance Coverage: A Patchwork

There’s no single answer to “does insurance cover GLP-1 medications?” It depends entirely on what kind of insurance you have, what the medication is prescribed for, and — increasingly — where you live.

Employer-Sponsored Insurance

This is where coverage has improved the most. According to KFF’s 2025 Employer Health Benefits Survey, 43% of employers with 5,000 or more workers now cover GLP-1 medications for weight loss — up from 28% just a year earlier.[2] That’s a significant jump, and the trend is still moving upward.

But “coverage” doesn’t always mean “affordable.” Many employer plans that cover GLP-1s still require:

• Prior authorization — your doctor has to submit paperwork proving you meet specific criteria before the insurer will approve it
• Step therapy — you may need to try (and fail on) a cheaper alternative first
• Specialty tier copays — even with coverage, your monthly cost might be $100-$300

If you have employer insurance, the first step is calling the number on the back of your card and asking specifically: “Does my plan cover [medication name] for [your diagnosis]?” Get it in writing if you can.

ACA Marketplace Plans

This is where things get frustrating. Less than 1% of ACA marketplace plans cover GLP-1 medications for weight loss.[3] The Affordable Care Act doesn’t require marketplace plans to cover anti-obesity medications, and most don’t. If your GLP-1 is prescribed for Type 2 diabetes, coverage is more likely — but for weight management alone, marketplace plans are largely a dead end right now.

Medicare

Medicare has historically been prohibited from covering weight loss medications — that’s been federal law since 2003. But that’s changing.

The BALANCE Model (officially announced by CMS in January 2026) is a demonstration program that will bring GLP-1 coverage to Medicare beneficiaries for the first time. Here’s the timeline:

• Bridge demonstration: July 2026 — limited rollout
• Full model launch: January 2027 — broader access
• Negotiated price: $245/month (down from list price)
• Estimated out-of-pocket: ~$50/month for beneficiaries[4]

This is a big deal. The $245 negotiated price came out of direct negotiations between the federal government and the manufacturers — part of a broader push that also produced the TrumpRx platform prices starting around $350/month and trending toward that $245 figure.[5]

If you’re on Medicare and have been waiting, there’s a real timeline now. Talk to your provider about getting documentation ready.

Medicaid

Medicaid coverage for GLP-1s varies dramatically by state. As of early 2026, only 13 state Medicaid programs cover GLP-1 medications for obesity.[8] And the picture is getting more complicated, not less — several states, including Pennsylvania, California, and Michigan, have been pulling back Medicaid coverage for weight loss medications in 2025-2026 due to budget concerns.

If you’re on Medicaid, check your state’s specific formulary (the list of covered medications). Your prescriber’s office can usually help with this.

VA (Veterans Affairs)

The VA does cover GLP-1 medications, but typically as non-formulary — meaning they’re not on the standard list and require additional authorization. Most VA facilities require enrollment in the MOVE! Weight Management Program and completion of step therapy (trying other treatments first) before approving a GLP-1.[8]

If you’re a veteran, ask your VA primary care provider about the MOVE! program as your pathway in.

TRICARE

Here’s one that caught a lot of people off guard: TRICARE for Life dropped coverage for weight loss medications on August 31, 2025. If you’re a military retiree or dependent who was relying on TRICARE for GLP-1 coverage, that benefit is gone. TRICARE Standard and Prime may still cover GLP-1s prescribed for diabetes, but weight management coverage has been eliminated for the TRICARE for Life population.

Manufacturer Savings Programs

This is where the rubber meets the road for a lot of people. Both Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) have created direct-to-patient programs that significantly reduce costs — and some of them don’t require insurance at all.

From my experience, these self-pay prices through the manufacturers are often better than what people pay through insurance with high-deductible plans. It’s worth running the numbers both ways before assuming insurance is the cheaper path.

Why Are These Drugs So Expensive?

This is a fair question, and the answer is complicated — but the short version is that it doesn’t have to be this way.

The Yale/JAMA study that found manufacturing costs of $0.89 to $4.73 per month also noted that other countries pay a fraction of U.S. prices for the same medications.[1] The gap isn’t about production costs or research recovery alone — it’s about a pricing system that allows it.

Practical Strategies for Reducing Costs

If you’re facing a high price tag, here are the paths people actually use:

1. Check every savings program first — visit NovoCare.com (for Ozempic/Wegovy) or LillyDirect.com (for Mounjaro/Zepbound). Even if you have insurance, a savings card might reduce your copay further.
2. Ask about the diabetes indication — if you have Type 2 diabetes in addition to weight management needs, the medication may be covered under the diabetes indication with broader insurance coverage. Same medication, different billing code.
3. Compare self-pay to insurance pricing — with some high-deductible plans, the manufacturer self-pay price ($299-$449/month) can be less than your insurance copay during deductible season.
4. Appeal denied claims — your prescriber's office can submit a letter of medical necessity. First-line appeals succeed more often than people expect. If the first appeal fails, ask about a peer-to-peer review.
5. Ask about patient assistance programs — if your income qualifies, manufacturer PAPs can cover the cost entirely. Novo Nordisk's program covers households up to 400% of the federal poverty level.
6. Watch for the Medicare BALANCE rollout — if you're on Medicare, the bridge demonstration starts July 2026 and the full model launches January 2027. That $50/month copay will be transformative.[4]

The Bottom Line

The cost picture for GLP-1 medications is bad — but it’s also the best it’s ever been, and it’s getting better. Manufacturer self-pay programs, Medicare negotiations, insurance savings cards, and direct-to-consumer pricing are all putting downward pressure on what people actually pay. Two years ago, if you didn’t have great employer insurance, you were largely out of luck. That’s no longer true.

It still takes work. You’ll probably make phone calls you don’t want to make and fill out forms you shouldn’t have to fill out. The system isn’t designed to be easy. But the paths exist, and more are opening.

Don’t let sticker shock end the conversation before it starts. The list price is not your price. Find out what your actual number is — and then decide from there.